Coloplast A/S CLPBY OTC

Coloplast A/S (CLPBY) reported declining year-over-year revenue growth of -4.3% through 2025-12 (TTM revenue vs prior-year TTM). Net income showed earnings decline of -18.6% YoY, reaching $1.4B in the latest quarter. The net profit margin is 19.7%, which is high. The company has maintained profitability in all 4 quarters. The gross margin is 73% (high), up 5.5pp vs the prior year. With a $15B market cap, MOAT composite score of 84/100 (strong competitive position).

Criteria proven by this page:

• GROWTH (40/100, Fail) — revenue or earnings are not growing
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 24-year annual history, the company was profitable in 24 of 24 years — a perfect long-term track record
• INCOME (55/100, Pass) — proves strong profitability and pricing power
• MOAT (84/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 72/100 with 4/7 criteria passed.